Pharmaceutical Executive, May 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, May 1, 2010
Features
Dealmaking Roundtable
By William Looney
A panel of bankers and industry executives discuss what's ahead in deals for 2010.
Code Orange
By Gopkiran Rao, Model N
How will US healthcare reform affect drug pricing, revenue, and compliance?
Pharma's Orphans
By Walter Armstrong
The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it?
Tech Toys 2: Revenge of the App
By George Koroneos
The new world of mobile applications is sparking creative platforms for reaching consumers and physicians.
The 2010 Pharm Exec 50 (pdf)
By Mark Mozeson, Oliver Wyman , Patrick Clinton, Oliver Wyman
One year after the rash of pharma megamergers, Pharm Exec's annual listing of the industry's top-selling companies looks a little different. Find out who disappeared from the list, and what up-and-coming companies finally broke into the top 50.
Columns
Weathering the Compliance Storm
By Matt Wallach, Veeva Systems
Timely and accessible information can help break through the firewall of regulation.
Healthcare Hung Up in the UK Election?
By Julian Upton
The three-way race for control of Parliament leaves the future of the British pharmaceutical industry in the balance.
How to Become a Commitment Catalyst?
By Kate Caldwell, Draftfcb
Marketers must focus on getting busy women the help they need in making critical decisions about their healthcare.
From the Editor
Five Policies for Pharma's Big 50
By William Looney
Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.
Washington Report
Pharma's Big Tradeoff
By Jill Wechsler
Under the new healthcare regime, pharma will ante up fees and rebates in return for expanded sales and safeguards.

ADVERTISEMENT

Click here